AGIO – Agios Pharmaceuticals, Inc is a biopharmaceutical company, engaged in the discovery and development of medicines for the treatment of cancer and genetic disorders.
AGIO – Agios Pharmaceuticals, Inc |
||
Fundamentals | Previously closed at | 50.35 |
Day’s high | 55.96 | |
Day’s low | 50.02 | |
P/E ratio | NA | |
EPS | -3.62 |
Analysts opinion | Agios Pharma announced positive results for its phase 1 Drug AG-348, used to treat anaemia. The stock was upgraded by Canaccord Genuity and J. P Morgan to “Buy”. Analyst confidence meter, a proprietary algorithm of Stockal gives 66% buy based on analyst ratings. |
Sentiments | AGIO fell, after having gained 8% Pre-Market today. The sentiment index is 100% negative according to Stockal proprietary algorithm. |
Social Media Pulse | The stock has 10% lower social media chatter than usual. |
EBIO – Eleven Biotherepeutics is a biopharmaceutical company, engages in the discovery and development of protein therapeutics to treat eye diseases
EBIO – Eleven Biotherepeutics, Inc |
||
Fundamentals | Previously closed at | 1.87 |
Day’s high | 1.98 | |
Day’s low | 1.62 | |
P/E ratio | NA | |
EPS | -1.78 |
Analyst opinion | EBIO announced a licensing deal with Hoffman La-Roche for development and commercialization of its treatment for eye disease. Under the agreement, EBIO will receive an upfront payment of $7.5 million and potential future payments of about $265 Million. Confidence Meter reads a 73% buy. This a proprietary algorithm of Stockal tracks Analyst confidence in the Stock. |
Sentiments | The sentiment index is 50% positive on Stockal proprietary algorithm. |
Social Media Pulse | The stock has 25% lower social chatter than usual. |
Disclaimer: This blog contains an aggregated view of analysts and opinions by the author. Do not consider this as financial advice. See http://stockal.com/legalities/